Non-Alcoholic Fatty Liver Disease and Nutrition: A Literature Review
DOI:
https://doi.org/10.17140/aftnsoj-2-130Keywords:
Non-Alcoholic Fatty Liver, Obesity, Patients, Weight lossAbstract
Non-alcoholic fatty liver disease (NAFLD) is considered as a well-known disease which is determined by without using alcohol. There is high prevalence of non-alcoholic fatty liver in the community and this condition potentially can progress to hepatic cirrhosis and hepatic defect.
References
Sanyal AJ. Technical review on non-alcoholic fatty liver disease. Gastroenterology. 2002; 123: 1705-1725. doi: 10.1053/ gast.2002.36572
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population based study and its association with biochemical and anthropometric measures. Liver Int. 2006; 26: 856-863. doi: 10.1111/j.1478-3231.2006.01311.x
Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003; 37: 1202-1219. doi: 10.1053/jhep.2003.50193
Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231. doi: 10.1056/NEJMra011775
Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology. 1995; 108: 1607
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin Liver Dis. 2001; 21: 17-26. Web site. http:// www.ncbi.nlm.nih.gov/pubmed/11296693. Accessed June 27, 2016
Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132: 112-117. doi: 10.7326/0003-4819-132-2- 200001180-00004
Bedogni G, Bellentani S. Fatty liver: How frequent is it and Open why? Ann Hepatol. 2004; 3: 63-65. Web site. http://www.medigraphic.com/pdfs/hepato/ah-2004/ah042d.pdf. Accessed June 27, 2016
Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917-923. doi: 10.1053/jhep.2003.50161
Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107: 450-455. doi: 10.1016/S0002- 9343(99)00271-5
Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D. Liver damage in obese patients. Obes Surg. 2002; 12: 802-804. doi: 10.1381/096089202320995592
Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004; 19: 854-858. doi: 10.1111/j.1440-1746.2004.03312.x
Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, andnon-alcoholic fatty liver disease. J Clin Endocrinol Metab. 2005; 90: 1578-1582. doi: 10.1210/jc.2004- 1024#sthash.TTXOh4G5.dpuf
Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic, steatosis and insulin resistance: Does etiology make a difference? J Hepatol. 2006; 44: 190-196. doi: 10.1016/j.jhep.2005.06.018
Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16: 421-427. Web site. http://journals.lww. com/co-lipidology/Abstract/2005/08000/Non-alcoholic_fatty_liver_disease_and_the_metabolic.6.aspx. Accessed June 27, 2016
Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as apredictor of non-alcoholic fatty liver disease. Ann Intern Med. 2005; 143: 722-728. doi: 10.7326/0003-4819-143- 10-200511150-00009
Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patientswith non-alcoholic fatty liver disease: The significance of dietary cholesterol. Scand J Gastroenterol. 2009; 44: 471-477. doi: 10.1080/00365520802588133
Musso G, Gambino R, De Michieli F, et al. Dietary habits andtheir relations to insulin resistance and postprandial lipemiain non-alcoholic steatohepatitis. Hepatology. 2003; 37: 909- 916. doi: 10.1053/jhep.2003.50132
Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked withfatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008; 22: 811-816. doi: 10.1155/2008/810961
Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Journal Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1998; 84: 137-144. doi: 10.1210/jcem.84.1.5371#sthash.1ZiBQiq2.dpuf
Lee JH, Rhee PL, Lee JK, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of non-alcoholic fatty liver in patients with normal body weight. Korean J Intern Med. 1998; 13: 10-14. doi: 10.3904/kjim.1998.13.1.10
Marchesini G, Brizi M, Bianchi G, et al. Non-alcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-1850. doi: 10.2337/diabetes.50.8.1844
Pagano G, Pacini G, Musso G, et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolicsyndrome: Further evidence for an etiologic association. Hepatology. 2002; 35: 367-372. doi: 10.1053/jhep.2002.30690
Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35: 373-379. doi: 10.1053/jhep.2002.30692
Cheung O, Sanyal AJ. Recent advances in non-alcoholic fatty liver disease. Curr Opin Gastroenterol. 2010; 26: 202-208
Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001; 21: 89-104. Web site. http://www.ncbi.nlm.nih. gov/pubmed/11296700. Accessed June 27, 2016
Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229. doi: 10.1016/0168-8278(91)90942-5
Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Non-alcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004; 39: 1647-1654. doi: 10.1002/hep.20251
Eriksson S, Eriksson KF, Bondesson L. Non-alcoholic steatohepatitis in obesity: A reversible condition. Acta Med Scand. 1986; 220: 83-88. doi: 10.1111/j.0954-6820.1986.tb02733.x
Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998; 22: 222-226. Web site. http://www.ncbi.nlm.nih.gov/pubmed/9539189. Accessed June 27, 2016
Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99: 1408-1413. Web site. http://www.ncbi.nlm.nih.gov/ pubmed/2210247. Accessed June 27, 2016
Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107. doi: 10.1016/S0168-NUTRITIONAL Open 8278(97)80287-5
Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009; 17: 2162-2168. doi: 10.1038/oby.2009.126
Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med. 2009; 360: 923-925. doi: 10.1056/ NEJMe0810291
Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res. 2003; 44: 2065-2072. doi: 10.1194/jlr.M300167-JLR200
Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005; 90: 2804-2809. doi: 10.1210/ jc.2004-1983#sthash.f50f9cxy.dpuf
Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemiain non-alcoholic steatohepatitis. Hepatology. 2003; 37: 909- 916. doi: 10.1053/jhep.2003.50132
McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004; 40: 386-393. doi: 10.1002/hep.20302
Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004; 279: 32345-32353. doi: 10.1074/jbc.M313478200
Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes. 2003; 52: 2453-2460. doi: 10.2337/diabetes.52.10.2453
Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and non-alcoholic fatty liver disease. Dig Dis Sci. 2004; 49: 1578-1583. doi: 10.1023/B:DDAS.0000043367.69470.b7
Toshimitsu K, Matsuura B, Ohkubo I, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007; 23: 46-52. doi: 10.1016/j.nut.2006.09.004
Machado MV, Ravasco P, Jesus L, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol. 2008; 43: 95-102. doi: 10.1080/00365520701559003
Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce SCIENCES Journal DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science. 1987; 237: 885-888. doi: 10.1126/science.3303333
Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003; 38: 1529-1539. doi: 10.1016/j. hep.2003.09.028
Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004; 39: 608-616. doi: 10.1002/hep.20093
Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006; 25: 816-823. doi: 10.1016/j.clnu.2006.01.027
Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther. 2006; 23: 1143-1151. doi: 10.1111/j.1365-2036.2006.02885.x
Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves non-alcoholic steatohepatitis. J Clin Gastroenterol. 2008; 42: 413-418. doi: 10.1097/MCG.0b013e31815591aa
Ibrahim A, Natrajan S, Ghafoorunissa R. Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism. 2005; 54: 240-246. Web site. http://www.ncbi.nlm.nih.gov/pubmed/15789505. Accessed June 27, 2016
Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997; 337: 1491-1499. doi: 10.1056/NEJM199711203372102
Machado RM, Stefano JT, Oliveira CP, et al. Intake of trans fatty acids causes non-alcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr. 2010; 140: 1127-1132. doi: 10.3945/jn.109.117937
Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G987-G995. doi: 10.1152/ajpgi.90272.2008
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003; 77: 1146-1155. Web site. http://ajcn.nutrition.org/content/77/5/1146. full. Accessed June 27, 2016 Open
Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: A meta-analysis. Am J Clin Nutr. 1998; 67: 577S- 582. Web site. http://www.ncbi.nlm.nih.gov/pubmed/9497173. Accessed June 27, 2016
Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content innonalcoholic fatty liver disease in rats. World J Gastroenterol. 2007; 13: 361-368. doi: 10.3748/WJG.v13.i3.361
Hernandez R, Martinez-Lara E, Canuelo A, et al. Steatosisrecovery after treatment with a balanced sunflower orolive oilbased diet: Involvement of perisinusoidal stellatecells. World J Gastroenterol. 2005; 11: 7480-7485. doi: 10.3748/wjg.v11. i47.7480
Szende B, Timar F, Hargitai B. Olive oil decreases liver damage in rats caused by carbon tetrachloride (CCl4). Exp Toxicol Pathol. 1994; 46: 355-359. doi: 10.1016/S0940-2993(11)80116-8
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J Hepatol. 2007; 47: 711-717. doi: 10.1016/j.jhep.2007.06.020
Kainuma M, Fujimoto M, Sekiya N, et al. Cholesterol-fed rabbit as a unique model of non-alcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006; 41: 971-980. doi: 10.1007/s00535-006-1883-1
Gaby AR. Adverse effects of dietary fructose. Altern Med Rev. 2005; 10: 294-306. Web site. http://www.altmedrev.com/ publications/10/4/294.pdf. Accessed June 27, 2016
Brownell KD, Farley T, Willett WC, et al. The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med. 2009; 361: 1599-1605. doi: 10.1056/NEJMhpr0905723
Duffey KJ, Popkin BM. Shifts in patterns and consumption of beverages between 1965 and 2002. Obesity. 2007; 15: 2739- 2747. doi: 10.1038/oby.2007.326
Schulze MB, Manson JE, Ludwig DS, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004; 292: 927-934. doi: 10.1001/jama.292.8.927
Poulsom R. Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol. 1986; 21: 104- 134. Web site. http://www.ncbi.nlm.nih.gov/pubmed/3523499. Accessed June 27, 2016
Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: A systematic review. Am J Clin Nutr. 2006; 84: 274-288. Web site. http://www.ncbi.nlm.nih.gov/pubmed/16895873. Accessed June 27, 2016 Journal
Vartanian LR, Schwartz MB, Brownell KD. Effects of soft drink consumption on nutrition and health: A systematic review and meta-analysis. Am J Public Health. 2007; 97: 667-675. doi: 10.2105/AJPH.2005.083782
Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009; 89: 1037-1042. doi: 10.3945/ajcn.2008.27140
Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: A meta-analysis. Diabetes Care. 2010; 33: 2477-2483. doi: 10.2337/dc10-1079
Herman RH, Zakim D, Stifel FB. Effect of diet on lipid metabolism in experimental animals and man. Fed Proc. 1970; 29: 1302-1307. Web site. http://www.ncbi.nlm.nih.gov/pubmed/4245709. Accessed June 27, 2016
Cave M, Deaciuc I, Mendez C, et al. Non-alcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007; 18: 184-195. doi: 10.1016/j.jnutbio.2006.12.006
Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48: 993-999. doi: 10.1016/j.jhep.2008.02.011
Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009; 51: 918- 924. doi: 10.1016/j.jhep.2009.05.033
Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology. 2010; 51: 1961- 1971. doi: 10.1002/hep.23535
Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC. Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr. 2000; 72: 912- 921. Web site. http://www.ncbi.nlm.nih.gov/pubmed/11010931. Accessed June 27, 2016
Pereira MA, Kartashov AI, Ebbeling CB, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet. 2005; 365: 36-42. doi: 10.1016/S0140-6736(04)17663-0
Kechagias S, Ernersson A, Dahlqvist O, et al. Fast-foodbased hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut. 2008; 57: 649-654. doi: 10.1136/gut.2007.131797
Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut. 2008; 57: 568-570. doi: 10.1136/gut.2007.143958 Open
Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 1967; 12: 198-208. doi: 10.1007/BF02233443
Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970; 282: 829-834. doi: 10.1056/NEJM197004092821502
Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229. Web site. http://www.ncbi.nlm.nih. gov/pubmed/2051001. Accessed June 27, 2016
Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99: 1408-1413. Web site. http://www.ncbi.nlm.nih.gov/ pubmed/2210247. Accessed June 27, 2016
Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107. doi: 10.1016/S0168- 8278(97)80287-5
Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol. 2005; 100: 1072-1081. doi: 10.1111/j.1572- 0241.2005.41334.x
Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology. 2010; 51: 121-129. doi: 10.1002/ hep.23276
Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with non-alcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009; 49: 80- 86. doi: 10.1002/hep.22575
Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33: 2156-2163. doi: 10.2337/dc10-0856
Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in non-alcoholic fatty liver disease. J Hepatol. 2005; 43: 1060-1066. doi: 10.1016/j.jhep.2005.06.008
St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009; 24: 399-407. doi: 10.1111/j.1440- 1746.2008.05694.x
Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight Journal reduction for non-alcoholic fatty liver disease with a homebased lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009; 44: 1203-1208. doi: 10.1007/s00535-009-0115-x
Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW 3rd, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: A randomized trial. JAMA. 1999; 281: 327-334. doi: 10-1001/ pubs.JAMA-ISSN-0098-7484-281-4-joc80889
Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005; 99: 1193-1204. doi: 10.1152/japplphysiol.00160.2005
LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol. 2005; 99: 1205-1213. doi: 10.1152/japplphysiol.00193.2005
Bauman AE. Updating the evidence that physical activity is good for health: An epidemiological review 2000-2003. J Sci Med Sport. 2004; 7: 6-19. Web site. http://www.ncbi.nlm.nih. gov/pubmed/15214597. Accessed June 27, 2016
Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20: 537-544. doi: 10.2337/diacare.20.4.537
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in non-alcoholic fatty liver disease: A population-based study. Hepatology. 2008; 48: 1791- 1798. doi: 10.1002/hep.22525
Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to non-alcoholic fatty liver disease. Gastroenterology. 2006; 130: 2023-2030. doi: 10.1053/j.gastro.2006.03.019
Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with non-alcoholic fatty liver disease. Hepatology. 2008; 47: 1158- 1166. doi: 10.1002/hep.22137
St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with non-alcoholic fatty liver disease. Hepatology. 2009; 50: 68- 76. doi: 10.1002/hep.22940
Sreenivasa Baba C, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2006; 21: 191-198. doi: 10.1111/j.1440- 1746.2005.04233.x Open
Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009; 50: 1105-1112. doi: 10.1002/hep.23129
Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009; 58: 1281-1288. doi: 10.1136/gut.2008.151977
Van Der Heijden GJ, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc. 2010; 42: 1973-1980. doi: 10.1249/MSS.0b013e3181df16d9
Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001; 286: 1218-1227. doi: 10.1001/jama.286.10.1218
Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med. 1998; 49: 235-261. doi: 10.1146/annurev.med.49.1.235
Hannukainen JC, Nuutila P, Borra R, et al. Increased physical activity decreases hepatic free fatty acid uptake: A study in human monozygotic twins. J Physiol. 2007; 578: 347-358. doi: 10.1113/jphysiol.2006.121368
Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005; 90: 3191-3196. doi: 10.1210/jc.2004-1959#sthash.hkbBx0DQ.dpuf
Iozzo P, Takala T, Oikonen V, et al. Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemia. Diabetes Care. 2004; 27: 2172-2177. doi: 10.2337/diacare.27.9.2172
Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: Exercise and type 2 diabetes. Med Sci Sports Exerc. 2000; 32: 1345-1360. Web site. http:// www.ncbi.nlm.nih.gov/pubmed/10912903. Accessed June 27, 2016
Pollock ML, Franklin BA, Balady GJ, et al. Resistance exercise in individuals with and without cardiovascular disease. Benefits, rationale, safety, and prescription: An advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, American heart association; position paper endorsed by the American College of Sports Medicine. Circulation. 2000; 101: 828-833. doi: 10.1161/01.CIR.101.7.828
Ibanez J, Izquierdo M, Arguelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Dia-Journal betes Care. 2005; 28: 662-667. doi: 10.2337/diacare.28.3.662
Tsuzuku S, Kajioka T, Endo H, Abbott RD, Curb JD, Yano K. Favorable effects of non-instrumental resistance training on fat distribution and metabolic profiles in healthy elderly people. Eur J Appl Physiol. 2007; 99: 549-555. doi: 10.1007/s00421- 006-0377-4
Banz WJ, Maher MA, Thompson WG, et al. Effects of resistance versus aerobic training on coronary artery disease risk factors. Exp Biol Med. 2003; 228: 434-440. Web site. http://ebm. sagepub.com/content/228/4/434.long. Accessed June 27, 2016
Ballor DL, Keesey RE. A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in males and females. Int J Obes. 1991; 15: 717- 726. Web site. http://www.ncbi.nlm.nih.gov/pubmed/1838100. Accessed June 27, 2016
Miller WJ, Sherman WM, Ivy JL. Effect of strength training on glucose tolerance and post-glucose insulin response. Med Sci Sports Exerc. 1984; 16: 539-543. Web site. http://www.ncbi. nlm.nih.gov/pubmed/6392812. Accessed June 27, 2016
Pratt M, Macera CA, Blanton C. Levels of physical activity and inactivity in children and adults in the United States: Current evidence and research issues. Med Sci Sports Exerc. 1999; 31: S526-S533. Web site. http://www.ncbi.nlm.nih.gov/ pubmed/10593523. Accessed June 27, 2016
Peterson JA. Get moving! Physical activity counseling in primary care. J Am Acad Nurse Pract. 2007; 19: 349-357. doi: 10.1111/j.1745-7599.2007.00239.x
Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care. 2007; 30: 203-209. doi: 10.2337/dc06-1128
Zhao G, Ford ES, Li C, Mokdad AH. Compliance with physical activity recommendations in US adults with diabetes. Diabet Med. 2008; 25: 221-227. doi: 10.1111/j.1464- 5491.2007.02332.x
Newton JL, Jones DE, Henderson E, et al. Fatigue in nonalcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008; 57: 807-813. doi: 10.1136/gut.2007.139303
Helmerhorst HJ, Wijndaele K, Brage S, Wareham NJ, Ekelund U. Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes. 2009; 58: 1776-1779. doi: 10.2337/ db08-1773
American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations Open revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006; 114: 82- 96. doi: 10.1161/CIRCULATIONAHA.106.176158
Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther. 2001; 15: 1667-1672. doi: 10.1046/j.1365-2036.2001.01083.x
Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38: 413-419. doi: 10.1053/jhep.2003.50316
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol. 2003; 98: 2485-2490. doi: 10.1111/j.1572-0241.2003.08699.x
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685. doi: 10.1056/NEJMoa0907929
Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The physicians’ health study II randomized controlled trial. JAMA. 2008; 300: 2123-2133. doi: 10.1001/jama.2008.600
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; CD007176. doi: 10.1002/14651858. CD007176.pub2
Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92: 2017-2029. doi: 10.1210/jc.2007-0298#sthash.zVEDzof1.dpuf
Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. Atherosclerosis. 2009; 205: 255-260. doi: 10.1016/j.atherosclerosis.2008.10.033
Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010; 152: 307-314. doi: 10.7326/0003-4819-152-5- 201003020-00009
Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010; 33: 1379-1381. doi: 10.2337/dc09-2321
Targher G, Bertolini L, Scala L, et al. Associations be-Journal tween serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007; 17: 517-524. doi: 10.1016/j.numecd.2006.04.002
Nseir WMA, Abu Mouch S, Grosovski M, Assy N. Association between 25-OH vitamin D concentrations and risk of coronary artery disease in patients with non alcoholic fatty liver disease. Hepatology. 2010; 52(Suppl 1)
Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51: 1889-1895. doi: 10.2337/diabetes.51.6.1889
Hanley AJ, Williams K, Festa A, et al. Insulin resistance atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes. 2004; 53: 2623-2632. doi: 10.2337/diabetes.53.10.2623
Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005; 28: 2913-2918. doi: 10.2337/diacare.28.12.2913
Marchesini G, Forlani G. NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002; 35: 497-499. doi: 10.1053/jhep.2002.31551
Fracanzani AL, Burdick L, Rasselli S, et al. Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with NAFLD: A case control study. J Hepatol. 2006; 44: S39
Ekstedt M, Fran’zen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Survival and causes of death in patients with elevated liver enzymes associated with NAFLD. J Hepatol. 2006; 44: S40
Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. Hepatology. 2005; 42: 473-480. doi: 10.1002/ hep.20781
Targher G, Bertolini L, Poli F, et al. Non-alcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54: 3541-3546. doi: 10.2337/ diabetes.54.12.3541
Jepsen P, Vilstrup H, Mellemkjaer L, et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology. 2003; 50: 2101-2104. Web site. http://www.ncbi.nlm.nih.gov/pubmed/14696473. Accessed June 27, 2016
Kessler A, Levy Y, Roth A, et al. Increased prevalence of ADVANCES IN FOOD TECHNOLOGY AND NUTRITIONAL SCIENCES ISSN 2377-8350 http://dx.doi.org/10.17140/AFTNSOJ-2-130 Open Journal NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology. 2005; 42(Suppl 1): A623
Bogin E, Avidar Y, Merom M. Biochemical changes in liver and blood during liver fattening in rats. J Clin Chem Clin Biochem. 1986; 24: 621-626. Web site. http://edoc.hu-berlin.de/oa/ degruyter/cclm.1986.24.9.621.pdf. Accessed June 27, 2016
Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53: 372-384. doi: 10.1016/j.jhep.2010.04.008
Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: Is there a difference? J Am Diet Assoc. 2007; 107: 92-99. doi: 10.1016/j.jada.2006.10.005
Anderson AS. How to implement dietary changes to prevent the development of metabolic syndrome. Br J Nutr. 2000; 83(Suppl 1): S165-S168. doi: 10.1017/S0007114500001112
Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med. 2001; 161: 218-227. doi: 10.1001/archinte.161.2.218
Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008; 93: S74-S80. doi: 10.1210/jc.2008-1399
Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Fatty Liver Italian Network. Behavior therapy for non-alcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008; 47: 746-754. Adv Food Technol Nutr Sci Open J Page 63
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Advances in Food Technology and Nutrition Sciences (AFTNS) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.